Zobrazeno 1 - 10
of 138
pro vyhledávání: ''
Autor:
Ring, A., Battisti, N.M.L., Reed, M.W.R., Herbert, E., Morgan, J.L., Bradburn, M., Walters, S.J., Collins, K.A., Ward, S.E., Holmes, G.R., Burton, Maria, Lifford, K., Edwards, A., Robinson, T.G., Martin, C., Chater, T., Pemberton, K.J., Brennan, A., Cheung, K.L., Todd, A., Audisio, R.A., Wright, J., Simcock, R., Green, T., Revell, D., Gath, J., Horgan, K., Holcombe, C., Winter, M.C., Naik, J., Parmeshwar, R., Gosney, M.A., Hatton, M.Q., Thompson, A.M., Wyld, L., Collins, K., Ward, S., Holmes, G., Morgan, J., Walters, S., Burton, M., Brain, K., Robinson, T., Pemberton, K., Shrestha, A., Nettleship, A., Richards, P., Harder, H., Audisio, R., Murray, C., Thomson, A.M., Gosney, M., Hatton, M., Armitage, F., Patnick, J., Revill, D., Winter, M.
Publikováno v:
British Journal of Cancer
Background Chemotherapy improves outcomes for high risk early breast cancer (EBC) patients but is infrequently offered to older individuals. This study determined if there are fit older patients with high-risk disease who may benefit from chemotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ed056944ecd27827ab3bd963813fe40
http://sro.sussex.ac.uk/id/eprint/101218/1/s41416-021-01388-9.pdf
http://sro.sussex.ac.uk/id/eprint/101218/1/s41416-021-01388-9.pdf
Autor:
James L. Thorne, Melina C. Teske, Robyn V. Broad, Andrew M. Hanby, Laura M. Wastall, Stacey J. Jones, Thomas A. Hughes
Publikováno v:
British Journal of Cancer
Background Triple negative breast cancers (TNBC) have poor prognoses despite aggressive treatment with cytotoxic chemotherapy. Cancer-associated fibroblasts (CAFs) are prominent in tumour stroma. Our hypothesis was that CAFs modulate chemotherapy sen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::027115557c95f3f47f1ecb119dec9f3d
Autor:
Sylwia Kopijasz, Corran Roberts, Victoria Y Strauss, Shibani Nicum, Andrew R Clamp, Marcia Hall, Richard D. Kennedy, Ana Montes, Charlie Gourley, Jacinta Abraham, Michael R.L. Stratford, Susana Banerjee, Lisa K. Folkes
Publikováno v:
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4, https://doi.org/10.1038/s41416-019-0674-4
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4
British Journal of Cancer
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4
British Journal of Cancer
BackgroundTumour cells with BRCA1/2 gene mutations demonstrate increased sensitivity to platinum and poly (ADP-ribose) polymerase (PARP) inhibitors. 6-mercaptopurine (6MP) was found to selectively kill BRCA-defective cells in a xenograft model as eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2b494bdec4a88dbce8776a6e9b65b9c
https://doi.org/10.1038/s41416-019-0674-4
https://doi.org/10.1038/s41416-019-0674-4
Autor:
Chris Twelves, Matthew Guo, Larisa Reyderman, Ishtiaq Husain Zubairi, R. Morrison, Nicola Cresti, Claudio Savulsky, Alan Anthoney, Vladimir Semiglazov, Ruth Plummer, T.R. Jeffry Evans, Constanta Timcheva
Publikováno v:
British Journal of Cancer
Background: \ud Capecitabine and eribulin are widely used as single agents in metastatic breast cancer (MBC) and have nonoverlapping toxicities.\ud \ud Methods: \ud In phase 1b (dose escalation), patients with advanced, treatment-refractory, solid tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97bccd2276eddef510b3a7b2fcc67aa0
https://eprints.whiterose.ac.uk/148290/1/s41416-018-0366-5.pdf
https://eprints.whiterose.ac.uk/148290/1/s41416-018-0366-5.pdf
Publikováno v:
British Journal of Cancer
Background: The aim of the present study was to investigate whether changes in the tissue expression of human epididymisspecific protein 4 (HE4) could predict therapy resistance and relapse after progestin hormone therapy for medium- and low-risk end
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a1f3dad813f940e895ecaa2529bb25e
https://hdl.handle.net/10037/24981
https://hdl.handle.net/10037/24981
Autor:
C. Rose, R Leonard, M Tubiana-Hulin, Denis Lacombe, J Vinholes, J Wildiers, J Michel, Robert E. Coleman, J Nortier, J. Ford, F. Mignolet, P Bastit
Publikováno v:
British Journal of Cancer
This study was designed to evaluate new bone resorption and tumour markers as possible alternatives to serial plain radiographs for the assessment of response to treatment. Thirty-seven patients with newly diagnosed bone metastases from breast cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76f16dd46c0774b038d4bedfedc3bf7f
Autor:
Oumar Camara, Carola Rabenstein, Cornelia Jörke, Klaus Hoeffken, Ingo B. Runnebaum, Katharina Pachmann, Anne Egbe, U. Hammer
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 135(4):643-647
In breast cancers, the gene for the growth factor receptor HER2 can be amplified leading to increased aggressiveness and metastasis formation. The monoclonal antibody trastuzumab prolongs relapse-free survival highly significantly but eventually many
Autor:
Tianfeng Wang, Ai-ping Lu, Yiqiang Liu, Yijun Zhou, Zhaoqing Fan, Tao Ouyang, Yuntao Xie, Jinfeng Li, Yingjian He
Publikováno v:
Breast Cancer Research and Treatment
This study aimed to compare the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer. Five-hundred and one patients with clinical stage I-III invasive breast cancer were randomly assig
Autor:
M E, Cazzaniga, L, Cortesi, A, Ferzi, L, Scaltriti, F, Cicchiello, M, Ciccarese, S, Della Torre, F, Villa, M, Giordano, C, Verusio, M, Nicolini, A R, Gambaro, L, Zanlorenzi, E, Biraghi, L, Legramandi, E, Rulli, Valter, Torri
Publikováno v:
Breast Cancer Research and Treatment
Purpose: The VICTOR-1 study demonstrated that the all-oral metronomic combination of vinorelbine and capecitabine is highly active and well tolerated in hormone receptor-positive/HER2-negative patients. The VICTOR-2 study was designed to confirm thes
Autor:
David Miles, José Baselga, Sandra M. Swain, Adam Knott, Graham Ross, Dino Amadori, Patrapim Sunpaweravong, Emma Clark, Vladimir Semiglazov
Publikováno v:
Breast Cancer Research and Treatment
Although the incidence of cancer increases with age, older patients are under-represented in cancer treatment trials, resulting in limited data availability in this patient population. Here we present results from pre-defined subgroup analyses conduc